Recent Company News

• 08:05 AM ET May 15, 2026
  

  Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

• 07:59 AM ET Apr 24, 2026
  

  Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

• 07:37 AM ET Apr 01, 2026
  

  Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

• 07:10 AM ET Jul 23, 2024
  

  Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)